Ottawa, ON (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has signed a partnership with CSA Animal Nutrition providing for the sales and distribution of OxC-beta™ Livestock (“OxC-beta”) by CSA in the United States. Under the terms of the agreement, CSA will coordinate commercial scale validation research with potential customers and fulfill a sales and distribution role with OxC-beta™ for poultry, swine and dairy cattle in the United States. This agreement provides Avivagen with an experienced partner with numerous established relationships throughout the United States.
“We’re very excited to be entering into this important relationship that will bring OxC-beta to this crucial market and allow for the sale of OxC-beta within the United States,” said Kym Anthony, Chairman and Interim CEO, Avivagen Inc. “With their extensive technical experience and relationships and ability to access the US livestock and poultry markets, CSA represents a strong partner for Avivagen. The timing is good given the regulatory process in the US is now completed and we look to add sales and distribution networks in new markets to significantly drive our sales.”
This US partnership provides Avivagen with access to 20% of the world’s Global Feed Market and encompasses poultry, swine and dairy cattle.
CSA’s unique business model provides nutrition solutions and services for meat, milk and egg producers, feed manufacturers and nutrition consultants. As an independent, science based and customer focused firm, CSA’s priorities are driven by nutrition for the animal and economics for its customers, providing quality solutions, services and products for a wide range of customers. In addition to providing core nutrition services, CSA will engage in screening, validating, and commercializing emerging nutrition technologies. As an independent firm, CSA has the flexibility and expertise to reach a variety of customers across numerous species, from integrated commercial livestock and poultry production companies and young animal product manufacturers to premix blenders, thereby enhancing the potential adoption and sale of OxC-beta.
About CSA Animal Nutrition
With a seasoned management team of experts who have an average of over 20 years experience and possess extensive industry experience, CSA provides science based independent recommendations as technology advances, markets change and consolidation occurs across the additives, premix and feed segments. CSA’s independence and flexibility empower it to align with strategic partners to validate and rapidly commercialize new technologies to serve multiple clients and species. Core nutrition services offered by CSA include nutrition program design, diet specifications and formula optimization based on customer objectives and goals. CSA provides independent research-based recommendations to help its customers achieve production and financial goals; CSA also helps its customer with sourcing of micro-ingredients and screening, validation, and application of new technologies such as OxC-beta. For more information on CSA Animal Nutrition, please visit their website at www.CSAAnimalNutrition.com. Avivagen takes no responsibility for the contents of the CSA website and the contents of such website are expressly not incorporated by reference in this press release.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan, New Zealand, Thailand and USA.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the anticipated outcomes or benefits to be achieved by Avivagen from the agreement with CSA, the expected success of the CSA relationship, the possibility for OxC-beta™ to be accepted into the U.S. market, CSA’s intention to accelerate market access and the commercial uptake of the OxC-beta™ product, the size of market opportunities and the potential for OxC-beta to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, CSA may not be as successful in its efforts to sell OxC-beta as currently anticipated, Avivagen’s products may not gain acceptance within the U.S. market, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, Avivagen may not be able to maintain its regulatory status in the United States or other jurisdictions due to many factors, some of which may be outside of its control, new market access may not occur in the timeline or manner expected by Avivagen and the market opportunities may not be as large as Avivagen anticipates due to many factors, many of which are outside of Avivagen’s control and Avivagen’s products may not gain market acceptance or regulatory approvals necessary to fulfill the global mandate to remove in-feed antibiotics as growth promoters. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Information as to market size if various jurisdictions is sourced by Avivagen from third parties. While Avivagen believes such third-party sources to be reliable, it has not independently verified such information and readers should not place undue weight on such information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
© 2019 GlobeNewswire, Inc. All Rights Reserved.
SOURCE: Avivagen Inc.